Abivax S.A.

ABVX Nasdaq SEC CIK 1956827
Follow Abivax Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 EUR · IFRS
Net income −€82M −108.1% vs same quarter last year
EPS, diluted -
Operating cash flow −€23.2M +30.7% vs same quarter last year
Operating income −€71.6M −67.4% vs same quarter last year
Net income by quarter
−€42.9M
−€38.8M
−€55.2M
−€39.4M
−€52.4M
−€48.4M
−€153.4M
−€82M
Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income6 fiscal years
−€400M−€300M−€200M−€100M€0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−€336.1M
FY24−€176.2M
FY23−€147.7M
FY22−€60.7M
FY21−€42.5M
FY20-
Free cash flowOperating cash flow minus capital expenditure
−€200M−€150M−€100M−€50M€0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−€161.3M
FY24−€154.7M
FY23−€97.4M
FY22−€54.2M
FY21−€45.1M
FY20-